• Connect with us
  • Information
    • About Us
    • Contact Us
    • Careers
    • Partnerships
    • Advertise With Us
    • Authors
    • Browse Topics
    • Events
    • Disclaimer
    • Privacy Policy
  • WORLD EDITION
    Australia
    North America
    World
Login
Investing News NetworkYour trusted source for investing success
  • WORLD EDITION
    North America
    Australia
    World
  • My INN
Videos
Companies
Press Releases
Private Placements
SUBSCRIBE
  • Reports & Guides
    • Market Outlook Reports
    • Investing Guides
  • Button
Resource
  • Precious Metals
  • Battery Metals
  • Base Metals
  • Energy
  • Critical Minerals
Tech
Life Science
Medical Device Market
Medical Device News
Medical Device Stocks
  • Medical Device Market
  • Medical Device News
  • Medical Device Stocks
medical device investing

Precipio Announces Q4 2017 Revenue at 350% of Previous Quarter

Written by Gabrielle Lakusta
|
Feb. 09, 2018 09:31AM PST

Specialty diagnostics company Precipio (NASDAQ:PRPO), announces preliminary, unaudited revenues for the 4th quarter of 2017 of approximately $945,000, representing three-fold from the previous quarter of approximately $270,000, as well as a three-fold year-over-year from the 4th quarter of 2016 revenues of approximately $316,000. As quoted in the press release: “Now that assets have been integrated and systems …

Specialty diagnostics company Precipio (NASDAQ:PRPO), announces preliminary, unaudited revenues for the 4th quarter of 2017 of approximately $945,000, representing three-fold from the previous quarter of approximately $270,000, as well as a three-fold year-over-year from the 4th quarter of 2016 revenues of approximately $316,000.

As quoted in the press release:

“Now that assets have been integrated and systems optimized, we have resumed our focus on sales growth and aggressively capturing market share with our disruptive diagnostic products and services,” commented Ilan Danieli, CEO. “Our team worked around the clock to ensure resumption of services within Q3-2017, and our sales growth in Q4 reflects that hard work. We will remain completely focused on continuing this revenue growth throughout the year.”

Click here to read the full press release.

medical device investing diagnostics company
The Conversation (0)

Go Deeper

AI Powered

MyDx Reports First Quarter Results

KORU Medical Systems Announces 27% Q3 Revenue Growth and Raises 2025 Revenue Guidance

Latest News

Outlook Reports

Resource
  • Precious Metals
    • Gold
    • Silver
  • Battery Metals
    • Lithium
    • Cobalt
    • Graphite
    • Electric Vehicles
  • Agriculture
  • Base Metals
    • Copper
    • Nickel
    • Zinc
  • Critical Metals
    • Rare Earths
  • Energy
    • Uranium
    • Oil and Gas
Tech
    • Artificial Intelligence
    • Cybersecurity
    • Robotics
    • Crypto
    • Cleantech
Life Science
    • Biotech
    • Cannabis
    • Pharmaceuticals

Featured Medical Device Investing Stocks

Cleo Diagnostics

Cleo Diagnostics (COV:AU)
COV:AU

Ocumetics Technology

Ocumetics Technology (OTC:CC)
OTC:CC

Bloom Health Partners

Bloom Health Partners (BLMH:CC)
BLMH:CC

Avricore Health

Avricore Health (AVCR:CC)
AVCR:CC
More featured stocks

Browse Companies

Resource
  • Precious Metals
  • Battery Metals
  • Energy
  • Base Metals
  • Critical Metals
Tech
Life Science
MARKETS
COMMODITIES
CURRENCIES